rupiya.io
⠋Loading...
0%
❯ Fetching dividend history...
Glenmark Pharmaceuticals Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Glenmark Pharmaceuticals Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹6,005 Cr | ₹6,563 Cr | ₹7,562 Cr | |||||||||
| Expenses | ₹4,914 Cr | ₹5,348 Cr | ₹6,125 Cr | |||||||||
| Operating Profit | ₹1,091 Cr | ₹1,214 Cr | ₹1,437 Cr | |||||||||
| OPM % | 18.0% | 18.0% | 19.0% | |||||||||
| Other Income | ₹11 Cr | ₹-180 Cr | ₹20 Cr | |||||||||
| Depreciation | ₹217 Cr | ₹300 Cr | ₹234 Cr | |||||||||
| Interest | ₹189 Cr | ₹190 Cr | ₹179 Cr | |||||||||
| Profit Before Tax | ₹697 Cr | ₹544 Cr | ₹1,044 Cr | |||||||||
| Tax | ₹697 Cr | ₹544 Cr | ₹1,044 Cr | |||||||||
| Net Profit | ₹546 Cr | ₹209 Cr | ₹743 Cr | |||||||||
| EPS (₹) | 20.0 | 7.7 | 26.3 | |||||||||
| Dividend Payout % | 0% | 26% | 8% |
Register free to see 9 more years.
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹3,100 Cr | ₹3,001 Cr | ₹3,036 Cr | ₹3,207 Cr | ||||||||
| Expenses | ₹2,626 Cr | ₹2,603 Cr | ₹2,599 Cr | ₹2,745 Cr | ||||||||
| Operating Profit | ₹474 Cr | ₹398 Cr | ₹437 Cr | ₹462 Cr | ||||||||
| OPM % | 15.0% | 13.0% | 14.0% | 14.0% | ||||||||
| Depreciation | ₹152 Cr | ₹135 Cr | ₹142 Cr | ₹141 Cr | ||||||||
| Interest | ₹97 Cr | ₹109 Cr | ₹112 Cr | ₹121 Cr | ||||||||
| Net Profit | ₹291 Cr | ₹-403 Cr | ₹173 Cr | ₹-62 Cr | ||||||||
| EPS (₹) | 9.7 | -15.2 | 5.3 | -2.9 |
Register free to see 8 more quarters.
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹27 Cr | ₹27 Cr | ₹28 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹2,956 Cr | ₹1,756 Cr | ₹3,601 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹3,267 Cr | ₹3,800 Cr | ₹3,988 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹2,176 Cr | ₹2,726 Cr | ₹2,575 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹8,427 Cr | ₹8,309 Cr | ₹10,193 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹3,091 Cr | ₹2,015 Cr | ₹2,594 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹0 Cr | ₹17 Cr | ₹17 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹5,331 Cr | ₹5,799 Cr | ₹7,039 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹8,427 Cr | ₹8,309 Cr | ₹10,193 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 9 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2015 | ₹854 Cr | ₹-566 Cr | ₹-98 Cr | — |
| Mar 2016 | ₹482 Cr | ₹-712 Cr | ₹199 Cr | — |
| Mar 2017 | ₹345 Cr | ₹-950 Cr | ₹699 Cr | — |
| Mar 2018 | ||||
| Mar 2019 | ||||
| Mar 2020 | ||||
| Mar 2021 | ||||
| Mar 2022 | ||||
| Mar 2023 | ||||
| Mar 2024 | ||||
| Mar 2025 |
Register free to see 9 more years.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +8.45% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.74% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -5.78% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +7.74% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +3.69% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.